Sit Investment Associates Inc. Buys 11,749 Shares of Stryker Corporation $SYK

Sit Investment Associates Inc. grew its stake in Stryker Corporation (NYSE:SYK) by 41.4% during the 4th quarter, Holdings Channel.com reports. The firm owned 40,152 shares of the medical technology company’s stock after acquiring an additional 11,749 shares during the period. Sit Investment Associates Inc.’s holdings in Stryker were worth $14,112,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently modified their holdings of SYK. Godfrey Financial Associates Inc. bought a new position in shares of Stryker in the fourth quarter valued at about $26,000. United Financial Planning Group LLC bought a new position in shares of Stryker in the third quarter valued at about $27,000. DJE Kapital AG bought a new position in shares of Stryker in the fourth quarter valued at about $28,000. CGC Financial Services LLC bought a new position in shares of Stryker in the fourth quarter valued at about $29,000. Finally, Strive Asset Management LLC bought a new position in shares of Stryker in the third quarter valued at about $30,000. 77.09% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on SYK shares. Canaccord Genuity Group dropped their price objective on shares of Stryker from $435.00 to $400.00 and set a “buy” rating on the stock in a research report on Friday, May 1st. Wells Fargo & Company dropped their price objective on shares of Stryker from $456.00 to $418.00 and set an “overweight” rating on the stock in a research report on Friday, May 1st. Robert W. Baird set a $385.00 price objective on shares of Stryker in a research report on Friday, May 1st. Truist Financial restated a “hold” rating and issued a $330.00 price target (down from $380.00) on shares of Stryker in a research note on Monday, May 4th. Finally, Wall Street Zen downgraded shares of Stryker from a “buy” rating to a “hold” rating in a research note on Saturday, May 16th. Sixteen investment analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $395.33.

Stryker Trading Down 1.0%

SYK stock opened at $305.82 on Friday. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.25 and a current ratio of 2.11. The company’s 50-day simple moving average is $316.75 and its 200 day simple moving average is $344.20. Stryker Corporation has a 52 week low of $281.00 and a 52 week high of $404.87. The company has a market capitalization of $117.24 billion, a PE ratio of 35.40, a price-to-earnings-growth ratio of 1.95 and a beta of 0.78.

Stryker (NYSE:SYK) last released its quarterly earnings results on Thursday, April 30th. The medical technology company reported $2.60 EPS for the quarter, missing the consensus estimate of $2.98 by ($0.38). Stryker had a net margin of 13.20% and a return on equity of 23.42%. The business had revenue of $6.02 billion during the quarter, compared to analyst estimates of $6.34 billion. During the same quarter last year, the company posted $2.84 earnings per share. The company’s revenue was up 2.6% on a year-over-year basis. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. As a group, sell-side analysts anticipate that Stryker Corporation will post 14.98 earnings per share for the current year.

Stryker Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, July 31st. Shareholders of record on Tuesday, June 30th will be paid a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a yield of 1.2%. The ex-dividend date is Tuesday, June 30th. Stryker’s dividend payout ratio is presently 40.74%.

Insiders Place Their Bets

In other Stryker news, Director Ronda E. Stryker sold 310,000 shares of the stock in a transaction dated Tuesday, May 26th. The shares were sold at an average price of $312.23, for a total transaction of $96,791,300.00. Following the sale, the director directly owned 1,924,880 shares in the company, valued at $601,005,282.40. This represents a 13.87% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, VP Robert S. Fletcher sold 4,544 shares of the stock in a transaction dated Thursday, May 28th. The stock was sold at an average price of $306.87, for a total transaction of $1,394,417.28. Following the sale, the vice president owned 10,582 shares in the company, valued at $3,247,298.34. The trade was a 30.04% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 323,264 shares of company stock worth $100,659,489 over the last ninety days. Corporate insiders own 4.60% of the company’s stock.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.